GlassScriptPhysician profile
Randy Gene Dotson
NPI 1467434787
$8,891.74
in general payments reported to CMS, 2019-2025
34 companies · $2,898 in 2025
The $2,898 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $182 · 2021: $623 · 2022: $1,277 · 2023: $1,501 · 2024: $1,831 · 2025: $2,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,230.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,084.56 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,399.01 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,142.94 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $682.16 | 2021-2025 | Cuvitru, Hyqvia, Glassia |
| Genzyme Corporation | $438.12 | 2023-2025 | |
| Grifols USA, LLC | $391.72 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $333.73 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $330.19 | 2019-2025 | |
| Genentech USA, INC. | $296.70 | 2021-2025 | Xolair |
| Insmed, INC. | $287.62 | 2024-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $199.47 | 2021-2025 | Zerbaxa, Recarbrio, Dificid |
| Pulmonx Corporation | $133.77 | 2022-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Vifor Pharma, INC. | $122.48 | 2024-2025 | Zemaira |
| Electromed, INC. | $116.80 | 2019-2025 | Smartvest |
| La Jolla Pharmaceutical Company | $114.28 | 2022-2024 | Giapreza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $105.59 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $92.38 | 2022-2025 | Opsumit |
| Mylan Specialty L.P. | $87.46 | 2020-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $77.86 | 2023 | Acthar |
| Philips North America LLC | $65.27 | 2019-2025 | Vest Therapy Und |
| Viatris Specialty LLC | $59.72 | 2025 | Yupelri |
| Pfizer INC. | $55.29 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $45.52 | 2023-2025 | Purified Cortrophin Gel |
| Amgen INC. | $41.95 | 2022-2023 | Tezspire |
| Sunovion Pharmaceuticals INC. | $34.03 | 2019 | |
| Octapharma USA, INC. | $23.50 | 2022 | |
| Csl Behring | $22.42 | 2024 | Kcentra |
| Ars Pharmaceuticals Operations, INC. | $20.93 | 2025 | Neffy |
| Verona Pharma, INC. | $19.63 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $18.18 | 2025 | Tyvaso |
| Ambu INC. | $16.61 | 2023 | |
| Gilead Sciences, INC. | $12.47 | 2021 | |
| Shire North American Group INC | $11.41 | 2019 | |
| Inogen, INC. | $7.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Dotson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.